Nicky Jaiswal,
Kabhi Khanna,
Km Priyanka Singh,
Rifat Siraj,
Kirti,
- Assistant Professor, Department of Pharmacy, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh Punjab, India
- Student, Department of Pharmacy, Adesh Institute of Pharmacy and Biomedical Science, Adesh University, Bathinda, Punjab, India
- Student, Department of Pharmacy, Adesh Institute of Pharmacy and Biomedical Science, Adesh University, Bathinda, Punjab, India
- Student, Department of Dental Sciences, Adesh Institute of Dental Science and Research, Adesh University, Bathinda, Punjab, India
- Student, Department of Dental Sciences, Adesh Institute of Dental Science and Research, Adesh University, Bathinda, Punjab, India
Abstract
Ebola virus disease (EVD) is one of the most dreadful and lethal viral infections, continuously generating threatening impacts on the health of the global population, especially in low-resource environments. This review provides an overview of Ebola vaccines, focusing on virology, vaccine development, clinical trials, regulatory approval, deployment plans, and ethical issues. Recombinant viral vector platforms have seen the development of successful vaccines, with the most prominent example being rVSV-ZEBOV, which has proven highly effective in outbreak situations. Both the safety and real-world effectiveness of these vaccines during Ebola outbreaks have been proven through clinical trials, such as the innovative ring vaccination studies, which have revolutionized the process of controlling Ebola epidemics. Vaccination as part of global preparedness systems, aided by stockpiling, emergency use authorizations, and augmented cold-chain logistics, has shifted responses toward preventive actions rather than merely reactive containment. Despite these successes, challenges remain associated with vaccine equity, access, duration of immunity, and community acceptance. Innovation in next-generation and multivalent vaccines, as well as approaches to deploying them ethically and equitably, is necessary to enhance outbreak preparedness. Overall, Ebola vaccines have transformed epidemic management and will serve as a valuable tool for handling future emerging infectious diseases.
Keywords: Ebola virus disease, Ebola vaccines, rVSV-ZEBOV, ring vaccination, outbreak preparedness, vaccine equity, global health security
[This article belongs to International Journal of Vaccines ]
Nicky Jaiswal, Kabhi Khanna, Km Priyanka Singh, Rifat Siraj, Kirti. Ebola Vaccination: From Outbreak Control to Global Preparedness. International Journal of Vaccines. 2026; 03(01):27-37.
Nicky Jaiswal, Kabhi Khanna, Km Priyanka Singh, Rifat Siraj, Kirti. Ebola Vaccination: From Outbreak Control to Global Preparedness. International Journal of Vaccines. 2026; 03(01):27-37. Available from: https://journals.stmjournals.com/ijv/article=2026/view=241210
References
1. Harland D. Infection Control: Understanding Diseases, Epidemiology, and Pathogen Transmission. Diana Harland continuing education course on infection control, NurseCE. com. Published. 2024. 2. Adikini S. Effective Disease Outbreak Response in Resource-Limited Settings (Master’s thesis, Fordham University). 3. Agbata C. A Mathematical Model for the Control of Ebola Virus Disease with Vaccination Effect. Journal of Mathematical Epidemiology. 2025 Jul 16;1(1):26-48. 4. Mugisha Emmanuel K. Building Trust in Vaccination Programs: Community Engagement Strategies. 5. Bhattacharjee S, Goswami S, Agarwal S, Bose A, Roy S. Filoviridae: Ebola Virus and Marburg Virus. InEmerging and Re-Emerging Viral Diseases 2026 (pp. 60-79). CRC Press. 6. Richardson CD, Acheson NH, editors. Fundamentals of molecular virology. John Wiley & Sons; 2025 Apr 22. 7. Hargrove H, Torres-Hurtado SA, Maury WJ, Zhang XF. Nanoscale Mechanical and Morphological Characterization of Ebolavirus-like Particles: Implications for Therapeutic Development. International journal of molecular sciences. 2025 May 28;26(11):5185. 8. Mahdizadeh S, Hamid KH, Roudsari MB, Jamil NY, Alfarttoosi KH, Taher SG, Alwan M, Jawad M, Mushtaq H, Soleimani M, Tabatabaei SN. Impact of emerging and re-emerging viral infections on periodontitis progression. Archives of Microbiology. 2026 Jan;208(1):59. 9. Kumar A, Ahmad F, Sah BK, Aljabali AA, Mishra Y, Mishra V. Advancements in viral vaccine development: from traditional to modern approaches. Exploration of Immunology. 2025 Jul 16;5:1003203. 10. Rojek A, Fieggen J, Apiyo P, Caluwaerts S, Fowler RA, Kaleebu P, Kojan R, Lado M, Lambe T, Dunning J, Horby P. Ebola disease: bridging scientific discoveries and clinical application. The Lancet Infectious Diseases. 2025 Mar 1;25(3):e165-76. 11. Mdluli T, Wollen-Roberts S, Merbah M, Beckman B, Li Y, Alrubayyi A, Curtis DJ, Shubin Z, Barrera MD, Boeckelman J, Duncan S. Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses. Science translational medicine. 2025 Apr 2;17(792):eadq2496. 12. O’Connor D, Clutterbuck EA, Gibani MM, Bibi S, Sanders KA, Makinson R, Kelly DF, Pollard AJ. Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine. Nature Communications. 2025 Jul 9;16(1):6331. 13. Street A, Kelly AH. Tolerable tests: Regulating diagnostic innovation in a global health emergency, lessons from Ebola. Science, Technology, & Human Values. 2025 Jul;50(4):744-71. 14. Thompson RN, Bansal S, Clapham H, Dyson L, Gutierrez MA, Hadley L, Hart WS, Heesterbeek H, Hollingsworth TD, House T, Howerton E. Infectious disease outbreak controllability: biological, social and public health factors. Proceedings of the Royal Society B: Biological Sciences. 2026 Jan 1;293(2063). 15. Chu VT, Spottiswoode N, Ward R, Yokoe DS, Ramirez-Avila L, Phelps MS, Glascock A, Crawford ED, Kamm J, Hao S, Li L. Implementation and outcomes of a rapid response genomic hospital epidemiology programme at an academic medical centre over 7 years. The Lancet Microbe. 2026 Jan 6. 16. Yap QR, Tan-Koi WC, Lim JC, Ooi EE. Pandemic Vaccine Development. 17. Attal-Juncqua AF. The Bioeconomy’s Role in Bolstering Health Security and Biodefense in the US (Doctoral dissertation, The Johns Hopkins University). 18. Taumar D, Singh AP, Sharma H, Gujjar A, Rajpoot I, Chaudhary V. Nano-vaccines in Pandemic Preparedness: Pioneering Rapid Development and Deployment for Global Immunity. Current gene therapy. 19. Janani L, Phillips R, Van Vogt E, Liu X, Waddington C, Cro S. Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century. Clinical and Experimental Immunology. 2025;219(1):uxae104. 20. Sarvepalli S, Pasika SR, Verma V, Thumma A, Bolla S, Nukala PK, Butreddy A, Bolla PK. A review on the stability challenges of advanced biologic therapeutics. Pharmaceutics. 2025 Apr 23;17(5):550. 21. Lundstrom K. Viral vector-based cancer vaccines. InCancer Vaccines: Methods and Protocols 2025 Apr 24 (pp. 101-127). New York, NY: Springer US. 22. KEITA M. Investigating innovative approaches and strategies for effective Ebola epidemic control: Case studies from Guinea and the Democratic Republic of the Congo. 23. Jethwaney J, Dhalaria P. Immunization Ecosystem: Perspectives and Strategies. Taylor & Francis; 2026 Jan 22. 24. Alotibi NF, Alotaibi TA, Alrasheedi AM, Alotaibi AF, Majrashi NH, Alotaibi SB, Alotaibi HS, Aldhaban JA, Khattar AA, Alotaibi SN, Alosaimi KA. From Prevention To Response: A Comprehensive Scientific Review Of Health Security. The Review of Diabetic Studies. 2025 Jun 10:301-14. 25. Zarro M, Bashlakova K, Dellisanti B, Brunone S, Villari P, De Vito C, Rosso A. Immunogenicity and safety of Ebola vaccines in children: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2025 Oct 30:108171. 26. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. Medicine. 2025 Jan 17;104(3):e41279. 27. Bissett C, Yong L, Spencer AJ, Ma FN, Courchesne EA, Koolaparambil Mukesh R, Ulaszewska M, Sampson A, Lucienne M, Kailath R, Morris S. Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms. Journal of Experimental Medicine. 2025 Oct 30;223(1):e20241529. 28. Spunde K, Korotkaja K, Sominskaya I, Zajakina A. Genetic adjuvants: A paradigm shift in vaccine development and immune modulation. Molecular Therapy Nucleic Acids. 2025 Jun 10;36(2). 29. Parr J, Chen YF, Damery S, Chaudhuri P, Grove A. Sub-national public health intelligence responses to disease outbreaks: A mixed-methods systematic review. Public Health. 2026 Jan 1;250:106055. 30. World Health Organization. Strategic plan for coronavirus disease threat management: advancing integration, sustainability, and equity, 2025–2030. 31. Alotibi NF, Alotaibi TA, Alrasheedi AM, Alotaibi AF, Majrashi NH, Alotaibi SB, Alotaibi HS, Aldhaban JA, Khattar AA, Alotaibi SN, Alosaimi KA. From Prevention to Response: A Comprehensive Scientific Review of Health Security. The Review of Diabetic Studies. 2025 Jun 10:301-14. 32. Mirza I, Lemango ET, Lindstrand A. Expanded Programme on Immunization (EPI): a legacy of 50 years and the road ahead. Vaccines. 2025 Jun 17;13(6):649. 33. Singh D. mRNA-Encoded antibodies as a next-generation therapeutic paradigm: a rapid and adaptive platform for the prevention and treatment of emerging and re-emerging infectious diseases—A critical review. Immunologic Research. 2026 Jan 12;74(1):7. 34. Eslami M, Fadaee Dowlat B, Yaghmayee S, Habibian A, Keshavarzi S, Oksenych V, Naderian R. Next-generation vaccine platforms: integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity. Vaccines. 2025 May 30;13(6):588. 35. Weibel D, Chen RT, Osokogu O, Ejekam C, Chandler R, Joshi J, Zuber P, Black S, Perez-Vilar S, Sevene E, Khagayi S. Vaccine Safety Issues in Resource-Limited Countries. InSpecial Issues in Pharmacovigilance in Resource-Limited Countries 2025 Oct 1 (pp. 211-247). Singapore: Springer Nature Singapore. 36. David I, Jeremiah RD. Bridging Trust and Collaborative Research in Low‐Income Contexts During Public Health Emergencies: A Sierra Leone Case Study. Health science reports. 2025 Apr;8(4):e70701. 37. Batool S, Chokkakula S, Jeong JH, Baek YH, Song MS. SARS-CoV-2 drug resistance and therapeutic approaches. Heliyon. 2025 Jan 30;11(2). 38. Scott GY, Aborode AT, Adesola RO, Khan M, Elebesunu EE, Oluwaseun AA, Ahmad M, Nibokun EO, Kwaku SD, Bakre AA, Chukwu PN. Enhancing vaccine quality and accessibility: strategies for efficient storage and distribution in resource-constrained environment. Outbreak Management and Response. 2025 Dec 29;1(1):2443439.
International Journal of Vaccines
| Volume | 03 |
| Issue | 01 |
| Received | 29/01/2026 |
| Accepted | 31/01/2026 |
| Published | 12/02/2026 |
| Publication Time | 14 Days |
Login
PlumX Metrics